Adma Biologics Inc (NASDAQ: ADMA) closed the day trading at $6.22 up 0.65% from the previous closing price of $6.18. In other words, the price has increased by $+0.04 from its previous closing price. On the day, 2496805 shares were traded. ADMA stock price reached its highest trading level at $6.36 during the session, while it also had its lowest trading level at $6.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of ADMA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 27.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 352.24. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 1.04.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 30 ’23 when Grossman Jerrold B bought 130,000 shares for $3.71 per share. The transaction valued at 482,144 led to the insider holds 443,265 shares of the business.
KWON YOUNG bought 25,000 shares of ADMA for $97,500 on Aug 24 ’23. The Director now owns 277,401 shares after completing the transaction at $3.90 per share. On Aug 22 ’23, another insider, Fong Bryant, who serves as the Director of the company, sold 1,433,304 shares for $3.87 each. As a result, the insider received 5,544,737 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 1.42B and an Enterprise Value of 1.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.50 while its Price-to-Book (P/B) ratio in mrq is 10.40. Its current Enterprise Value per Revenue stands at 5.85 whereas that against EBITDA is 294.84.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $6.41, while it has fallen to a 52-week low of $2.94. The 50-Day Moving Average of the stock is 5.25, while the 200-Day Moving Average is calculated to be 4.16.
Shares Statistics:
Over the past 3-months, ADMA traded about 2.63M shares per day on average, while over the past 10 days, ADMA traded about 4.14M shares per day. A total of 226.06M shares are outstanding, with a floating share count of 218.15M. Insiders hold about 4.41% of the company’s shares, while institutions hold 74.30% stake in the company. Shares short for ADMA as of Feb 29, 2024 were 6.72M with a Short Ratio of 2.56, compared to 6.84M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.95% and a Short% of Float of 3.09%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.32 and $0.28 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.5, with 4 analysts recommending between $0.51 and $0.48.
Revenue Estimates
4 analysts predict $77.27M in revenue for the current quarter. It ranges from a high estimate of $79.7M to a low estimate of $76M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $56.91M, an estimated increase of 35.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $81.27M, an increase of 35.20% less than the figure of $35.80% in the same quarter last year. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $78.4M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $337M, while the lowest revenue estimate was $331.9M, resulting in an average revenue estimate of $333.87M. In the same quarter a year ago, actual revenue was $258.21M, up 29.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $389.87M in the next fiscal year. The high estimate is $395.5M and the low estimate is $383.5M. The average revenue growth estimate for next year is up 16.80% from the average revenue estimate for this year.
